RESUMO
The hot flush is the most characteristic and often the most distressing symptom of the menopause. It is a unique feature and yet the mechanism and health implications are still not fully understood. This review summarizes some of the current thoughts on factors contributing to flushing, the physiological, vascular and neuroendocrine changes associated with flushing and the possible cardiovascular and other health implications for women experiencing hot flushes. Therapy is not discussed.
Assuntos
Fogachos/fisiopatologia , Animais , Regulação da Temperatura Corporal , Encéfalo/fisiopatologia , Doenças Cardiovasculares , Estrogênios/deficiência , Feminino , Fogachos/epidemiologia , Humanos , Imageamento por Ressonância Magnética , Memória , Menopausa/fisiologia , Sistemas Neurossecretores/fisiopatologia , Ovário/fisiopatologia , Sudorese , VasodilataçãoRESUMO
Menopausal women very often complain of vulvovaginal atrophy (VVA)-related symptoms, which mainly include dryness, irritation, dyspareunia and pain. The ideal therapeutic approach is to use systemic or intravaginal estrogen, which has proved to be effective. However, because of safety concerns that were raised after the publication of the Women's Health Initiative data, non-estrogenic and non-hormonal therapies for VVA have been developed and heavily promoted. Many menopause specialists believe that the flow of information on the newer products indicated for VVA seems to include an inaccurate message, which downgrades the use of estrogenic preparations and upgrades modern non-estrogenic therapies. Both media and medical sources have created an atmosphere of exaggerated worries over intravaginal estrogen therapies, which are not substantiated by hard clinical facts.
Assuntos
Comunicação , Terapia de Reposição de Estrogênios/efeitos adversos , Estrogênios/administração & dosagem , Vagina/patologia , Vulva/patologia , Atrofia/complicações , Atrofia/tratamento farmacológico , Estrogênios/efeitos adversos , Medicina Baseada em Evidências , Feminino , Humanos , Menopausa , Preferência do Paciente , Guias de Prática Clínica como Assunto , Padrões de Prática MédicaRESUMO
BACKGROUND: In an integrated overview of the benefits and risks of menopausal hormone therapy (HT), the Women's Health Initiative (WHI) investigators have claimed that their 'findings do not support use of this therapy for chronic disease prevention'. In an accompanying editorial, it was claimed that 'the WHI overturned medical dogma regarding menopausal [HT]'. OBJECTIVES: To evaluate those claims. METHODS: Epidemiological criteria of causation were applied to the evidence. RESULTS: A 'global index' purporting to summarize the overall benefit versus the risk of HT was not valid, and it was biased. For coronary heart disease, an increased risk in users of estrogen plus progestogen (E + P), previously reported by the WHI, was not confirmed. The WHI study did not establish that E+ P increases the risk of breast cancer; the findings suggest that unopposed estrogen therapy (ET) does not increase the risk, and may even reduce it. The findings for stroke and pulmonary embolism were compatible with an increased risk, and among E+ P users there were credible reductions in the risk of colorectal and endometrial cancer. For E+ P and ET users, there were credible reductions in the risk of hip fracture. Under 'worst case' and 'best case' assumptions, the changes in the incidence of the outcomes attributable to HT were minor. CONCLUSIONS: Over-interpretation and misrepresentation of the WHI findings have damaged the health and well-being of menopausal women by convincing them and their health professionals that the risks of HT outweigh the benefits.
Assuntos
Neoplasias da Mama/epidemiologia , Doença das Coronárias/epidemiologia , Interpretação Estatística de Dados , Estrogênios/uso terapêutico , Terapia de Reposição Hormonal , Progestinas/uso terapêutico , Viés , Neoplasias da Mama/induzido quimicamente , Fatores de Confusão Epidemiológicos , Doença das Coronárias/induzido quimicamente , Estrogênios/efeitos adversos , Feminino , Terapia de Reposição Hormonal/efeitos adversos , Humanos , Menopausa , Progestinas/efeitos adversos , Medição de RiscoRESUMO
OBJECTIVE: To examine the relationships between temperature, season (summer versus winter), lifestyle, health, mood, beliefs, and experience of hot flushes and night sweats (HFNS), amongst mid-aged women living in the United Arab Emirates (UAE). METHODS: The UAE climate is hyper-arid, being a hot desert climate, with warm winters and hot summers. A total of 372 peri- and postmenopausal women, aged from 45 to 55 years, from urban UAE regions were included. Data were collected during both summer and winter months. Participants completed questionnaires eliciting information about sociodemographics, HFNS (prevalence, frequency and problem-rating), health and lifestyle (body mass index (BMI), diet, exercise), mood (Women's Health Questionnaire) and menopause attributions and beliefs (Menopause Representations Questionnaire). RESULTS: HFNS were currently being experienced by 46.5% of women, with an average weekly frequency of five and problem-rating of 5.7/10. Seasonal variation in temperature was not associated with prevalence, frequency or problem-rating. Hot flush prevalence was associated with poor health, life satisfaction, mood, employment, lower BMI and diet. Higher frequency was associated with higher BMI and more years since the last period. HFNS were more problematic mainly for women who reported lower life satisfaction and held more negative beliefs about the menopause. CONCLUSIONS: In this UAE study, temperature and seasonal temperature variation did not appear to influence HFNS-reporting, but health, life satisfaction, BMI, beliefs and lifestyle factors partially explained women's experiences of menopausal symptoms. A qualitative study might provide further information about the meanings of HFNS and menopause amongst UAE women.
Assuntos
Emoções/fisiologia , Fogachos , Menopausa , Estações do Ano , Sudorese/fisiologia , Sistema Vasomotor/fisiopatologia , Altitude , Índice de Massa Corporal , Clima , Cultura , Feminino , Disparidades nos Níveis de Saúde , Fogachos/epidemiologia , Fogachos/etiologia , Fogachos/fisiopatologia , Fogachos/psicologia , Humanos , Estilo de Vida , Menopausa/fisiologia , Menopausa/psicologia , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Estatística como Assunto , Inquéritos e Questionários , Temperatura , Emirados Árabes Unidos/epidemiologiaRESUMO
OBJECTIVE: To examine the relationships between climate (season, temperature, humidity), lifestyle, health, mood and beliefs and experience of hot flushes and night sweats amongst mid-aged women living in eight urban Indian centers. METHODS: A total of 717 peri- and postmenopausal women, aged 45-55 years, from urban centers in different regions of India were included. Data were collected during both summer and winter months. Participants completed questionnaires eliciting information about sociodemographics, hot flushes (prevalence, frequency and problem-rating), health and lifestyle (body mass index, diet, exercise, alcohol use), mood (Women's Health Questionnaire) and attributions and beliefs (Menopause Representations Questionnaire). RESULTS: The prevalence of vasomotor symptoms was low, with 34% of the sample reporting hot flushes and/or night sweats. Seasonal variation in temperature was not associated with hot flush prevalence, frequency or problem rating. Hot flush prevalence was mainly associated with higher anxiety and intake of spicy foods, frequency with (older) age and (more) frequent exercise, while hot flushes were more problematic for women who reported poorer general health and more negative beliefs about menopause. CONCLUSIONS: In this study of Indian women, seasonal temperature variation did not appear to influence hot flush reporting. Health, mood, beliefs and lifestyle factors appear to explain some, but not all, of the variance in experience of menopausal symptoms.
Assuntos
Emoções/fisiologia , Fogachos , Menopausa , Estações do Ano , Sudorese/fisiologia , Sistema Vasomotor/fisiopatologia , Altitude , Índice de Massa Corporal , Clima , Cultura , Feminino , Disparidades nos Níveis de Saúde , Fogachos/epidemiologia , Fogachos/etiologia , Fogachos/fisiopatologia , Fogachos/psicologia , Humanos , Índia/epidemiologia , Estilo de Vida , Menopausa/fisiologia , Menopausa/psicologia , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Estatística como Assunto , Inquéritos e Questionários , Temperatura , População UrbanaAssuntos
Terapia de Reposição de Estrogênios , Menopausa , Neoplasias da Mama/induzido quimicamente , Doenças Cardiovasculares/prevenção & controle , Consenso , Conferências de Consenso como Assunto , Neoplasias do Endométrio/induzido quimicamente , Terapia de Reposição de Estrogênios/efeitos adversos , Terapia de Reposição de Estrogênios/métodos , Medicina Baseada em Evidências , Feminino , Promoção da Saúde , Humanos , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/prevenção & controle , Insuficiência Ovariana Primária/tratamento farmacológico , Progestinas/administração & dosagem , Fatores de Risco , Sociedades Médicas , Tromboembolia/induzido quimicamenteRESUMO
For many years it has been perceived wisdom that hormone replacement therapy for women with a uterus should include a progestin to prevent the proliferative effects of estrogen on the endometrium and endometrial cancer. But, with the reports from the Women's Health Initiative (WHI) and Million Women Study indicating that such regimens are associated with an increased risk of breast cancer, whereas unopposed estrogen may not increase this risk, or even reduce it, it is pertinent to reassess the merits of adding a progestin. In addition, the suggestion from the WHI that the effects of estrogen and progestins are a 'class effect' are clearly inaccurate, as there is particular evidence from the French E3N cohort studies of differential effects of progestins, with progesterone and dydrogesterone additions showing no increase in risk of breast cancer. The data are presented but an answer to the posed question remains unclear and as usual dependent on the circumstances and views of each individual woman and her medical adviser.
Assuntos
Terapia de Reposição de Estrogênios/métodos , Menopausa , Progestinas/administração & dosagem , Neoplasias da Mama/induzido quimicamente , Hiperplasia Endometrial , Neoplasias do Endométrio/induzido quimicamente , Neoplasias do Endométrio/prevenção & controle , Terapia de Reposição de Estrogênios/efeitos adversos , Feminino , Humanos , Progestinas/efeitos adversos , Fatores de Risco , Saúde da MulherRESUMO
OBJECTIVE: To examine the relationship between climate (including altitude, temperature, humidity and annual range of temperature) and experience of hot flushes and night sweats amongst Spanish-speaking mid-aged women living in five urban centers. METHODS: A total of 896 peri- and postmenopausal women from centers in Chile (Santiago de Chile), Ecuador (Guayaquil and Quito), Panama (Panama City) and Spain (Madrid) completed questionnaires eliciting information about sociodemographics, hot flushes (prevalence, frequency and problem-rating), health and lifestyle (body mass index, diet, exercise, alcohol use) and mood (Women's Health Questionnaire). RESULTS: There was a wide range of altitude and temperature in the participating centers. Of the sample, 58.5% (524/896) were currently experiencing vasomotor symptoms. Prevalence was associated with higher temperatures, while hot flushes were more frequent and problematic for women living in higher temperature and lower altitudes. Hot flush variables were not associated with seasonal variation in temperature. When health and lifestyle variables were included as covariates in regression analyses, prevalence was best predicted by age (younger), poor general health, more depressed mood and anxiety; hot flush frequency by anxiety, temperature, life satisfaction (lower), age (higher), regular strenuous exercise (more strenuous exercise more frequent), and a diet including regular hot spicy food intake. Hot flush problem-rating was best predicted by anxiety, life satisfaction, altitude (lower more problematic), any regular exercise (more exercise less problematic), and depressed mood. CONCLUSIONS: In this study of Spanish-speaking women, those living in countries with higher temperatures and lower altitudes reported more frequent and problematic hot flushes.
Assuntos
Altitude , Clima , Fogachos/epidemiologia , Hiperidrose/epidemiologia , Perimenopausa/fisiologia , Pós-Menopausa/fisiologia , Temperatura , Fatores Etários , Análise de Variância , Distribuição de Qui-Quadrado , Chile , Intervalos de Confiança , Equador , Exercício Físico , Feminino , Alimentos , Humanos , Idioma , Pessoa de Meia-Idade , Razão de Chances , Panamá , Perimenopausa/psicologia , Pós-Menopausa/psicologia , Prevalência , Espanha , População Urbana , Sistema Vasomotor/fisiologiaRESUMO
The quality of life of countless menopausal women world-wide has been significantly diminished following the sensationalist reporting of the Women's Health Initiative (WHI) and the resulting 50% or more decline in the use of hormone replacement therapy (HRT) over the subsequent 10 years. Quality of life is difficult to measure as there are so many contributing factors and a large number of different instruments, some of which assess general health and only a few which specifically include symptoms related to menopause. HRT improves quality of life of symptomatic menopausal women and some studies of the effects of HRT provide reliable evidence on quality of life other than reduction in vasomotor symptoms. Until there is a better understanding of the minimal risks of HRT for the majority of women, too many will continue to suffer a reduced quality of life unnecessarily.
Assuntos
Terapia de Reposição de Estrogênios , Menopausa , Qualidade de Vida , Saúde da Mulher , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
OBJECTIVE: An overview of the current knowledge on the etiology and treatment of vasomotor symptoms in postmenopausal women. MATERIALS AND METHODS: Acknowledged experts in the field contributed a brief assessment of their areas of interest which were combined and edited into the final manuscript. RESULTS: Women around the world experience vasomotor symptoms as they enter and complete the menopause transition. Vasomotor symptoms, specifically hot flushes, are caused by a narrowing of the thermoneutral zone in the brain. This effect, although related to estrogen withdrawal, is most likely related to changes in central nervous system neurotransmitters. Peripheral vascular reactivity is also altered in symptomatic women. Estrogen replacement therapy is the most effective treatment for hot flushes. Of the other interventions investigated, selective serotonin and selective norepinephrine reuptake inhibitors and gabapentin show efficacy greater than placebo. Objective monitoring of hot flushes indicates a robust improvement with hormone replacement therapy but little to no change with placebo. These data suggest that the subjective assessment of responses to therapy for vasomotor symptom results in inaccurate data. Hot flushes have recently been associated with increased cardiovascular risks and a lower incidence of breast cancer, but these data require confirmation. CONCLUSIONS: Vasomotor symptoms are experienced by women of all ethnic groups. They are caused by changes in the central nervous system associated with estrogen withdrawal and are best treated with estrogen replacement therapy. Objective monitoring of hot flushes indicates that placebo has little to no effect on their improvement. Subjective assessments of hot flushes in clinical trials may be inaccurate based on objective measurement of the frequency of hot flushes. Based on preliminary reports, women experiencing hot flushes have an increased risk of cardiovascular disease and a reduced incidence of breast cancer.
Assuntos
Fogachos , Menopausa/fisiologia , Adulto , Regulação da Temperatura Corporal , Encéfalo/fisiologia , Neoplasias da Mama , Doenças Cardiovasculares , Terapia de Reposição de Estrogênios , Estrogênios/fisiologia , Feminino , Fogachos/tratamento farmacológico , Fogachos/epidemiologia , Fogachos/etiologia , Humanos , Pessoa de Meia-Idade , Neurotransmissores/fisiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco , Sudorese , Sistema VasomotorAssuntos
Procedimentos Clínicos/normas , Terapia de Reposição de Estrogênios , Pós-Menopausa , Saúde da Mulher , Neoplasias da Mama/etiologia , Neoplasias da Mama/metabolismo , Neoplasias da Mama/prevenção & controle , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/prevenção & controle , Cálculos da Dosagem de Medicamento , Terapia de Reposição de Estrogênios/efeitos adversos , Terapia de Reposição de Estrogênios/métodos , Terapia de Reposição de Estrogênios/normas , Feminino , Neoplasias dos Genitais Femininos/etiologia , Neoplasias dos Genitais Femininos/metabolismo , Neoplasias dos Genitais Femininos/prevenção & controle , Comportamentos Relacionados com a Saúde , Promoção da Saúde , Humanos , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/metabolismo , Osteoporose Pós-Menopausa/prevenção & controle , Neoplasias Ovarianas/etiologia , Neoplasias Ovarianas/metabolismo , Neoplasias Ovarianas/prevenção & controle , Pós-Menopausa/efeitos dos fármacos , Pós-Menopausa/metabolismo , Qualidade de Vida , Medição de RiscoRESUMO
Unlike hot flushes and night sweats which resolve spontaneously in time, atrophic symptoms affecting the vagina and lower urinary tract are often progressive and frequently require treatment. The prevalence of vaginal dryness increases as a woman advances through the postmenopausal years, causing itching, burning and dyspareunia, and sexual activity is often compromised. But, despite the various safe and effective options, only a minority (about 25% in the Western world and probably considerably less in other areas) will seek medical help. Some of this reluctance is due to the adverse publicity for hormone replacement therapy (HRT) over recent years that has suggested an increased risk of breast cancer, heart disease and stroke. But, regardless of whether these scares are justified, local treatment of vaginal atrophy is not associated with these possible risks of systemic HRT. Other reasons for the continued suffering in silence may be cultural and an understandable reluctance to discuss such matters, particularly with a male doctor, but the medical profession must also take much of the blame for failing to enquire of all postmenopausal women about the possibility of vaginal atrophic symptoms. Vaginal dryness can be helped by simple lubricants but the best and most logical treatment for urogenital atrophy is to use local estrogen. This is safe, effective and with few contraindications. It is hoped that these guidelines and recommendations, produced to coincide with World Menopause Day 2010, will help to highlight this major cause of distress and reduced quality of life and will encourage women and their medical advisers all over the world to seek and provide help.
Assuntos
Pós-Menopausa , Vagina/patologia , Doenças Vaginais/terapia , Administração Intravaginal , Adulto , África Subsaariana , Ásia , Atrofia , Atitude Frente a Saúde , Líquidos Corporais/fisiologia , Cultura , Dispareunia/etiologia , Estrogênios/administração & dosagem , Estrogênios/efeitos adversos , Estrogênios/deficiência , Estrogênios/uso terapêutico , Europa (Continente) , Feminino , Humanos , Concentração de Íons de Hidrogênio , Índia , América Latina , Lubrificantes/uso terapêutico , Pessoa de Meia-Idade , Oriente Médio , Pós-Menopausa/fisiologia , Qualidade de Vida , Disfunções Sexuais Fisiológicas/etiologia , Disfunções Sexuais Fisiológicas/terapia , Uretra/patologia , Doenças Urológicas/etiologia , Vagina/químicaRESUMO
OBJECTIVE: To evaluate the efficacy and safety of a transdermal testosterone patch (TTP, 300 microg/day) in naturally menopausal women with hypoactive sexual desire disorder (HSDD). METHODS: A total of 272 naturally menopausal women, predominantly not using hormone therapy, were randomized in this 6-month, placebo-controlled, double-blind, multicenter study to receive twice weekly either TTP or an identical placebo. Efficacy endpoints measured were the 4-week frequency of satisfying sexual episodes (SSE) using the Sexual Activity Log, the sexual desire domain of the Profile of Female Sexual Function and distress by the Personal Distress Scale. Safety was assessed by adverse events, laboratory parameters and hormone levels. RESULTS: The TTP group demonstrated significant improvements in SSE (p = 0.0089) as well as in sexual desire (p = 0.0007) and reduced personal distress (p = 0.0024) versus placebo at 6 months (intent-to-treat analysis, n = 247). The results were significant for all three endpoints in the subgroup (n = 199) not using hormone therapy. Similar numbers of women treated with placebo and TTP discontinued (n = 39, 27.5% vs. n = 26, 20%), reported adverse events (including application site reactions) (n = 101, 71.1% vs. n = 81, 62.3%) and withdrew due to adverse events (n = 20, 14.1% vs. n = 9, 6.9%). No clinically relevant changes were noted in laboratory parameters. Serum free and total testosterone levels increased from baseline in the TTP group (geometric means 5.65 pg/ml and 67.8 ng/dl, respectively, at week 24) within the physiological range; no changes were seen in estradiol and sex hormone binding globulin levels. CONCLUSIONS: TTP was effective in treating HSDD and improving sexual function in this study of naturally menopausal women with and without concurrent hormone therapy.
Assuntos
Estradiol/uso terapêutico , Libido/efeitos dos fármacos , Disfunções Sexuais Fisiológicas/tratamento farmacológico , Testosterona/uso terapêutico , Administração Cutânea , Análise de Variância , Método Duplo-Cego , Estradiol/administração & dosagem , Terapia de Reposição de Estrogênios , Feminino , Humanos , Menopausa , Pessoa de Meia-Idade , Testosterona/administração & dosagem , Testosterona/efeitos adversos , Resultado do TratamentoRESUMO
OBJECTIVES: We previously found differences in experience of menopausal symptoms between a migrated Asian sample of women from the Indian subcontinent living in the UK (UKA), and matched samples of UK Caucasian women (UKC) and Asian women living in Delhi, India (DEL). This study aims to explain these differences using quantitative and qualitative methods. METHODS: A total of 153 peri- and postmenopausal women aged 45-55 years (52 UKA, 51 UKC and 50 DEL) were interviewed about their experience of menopause, lifestyle and health. The current study combines a quantitative analysis of potential predictors (sociodemographic variables, mood, lifestyle, ethnicity, country of residence and religion) of vasomotor symptoms and a qualitative thematic content analysis of descriptions of experience of menopause. RESULTS: Country of residence and anxiety best predicted vasomotor symptoms, while religion, ethnicity, age of menopause and lifestyle factors did not. Within the UK Asian sample, poor general health, anxiety and less acculturation were predictors of vasomotor symptoms. Qualitative analyses revealed cultural differences in symptoms and beliefs about the menopause. CONCLUSIONS: These results challenge assumptions about migrated Asian populations living in western cultures and the qualitative data provides information that might increase understanding of the experience and meanings of menopause amongst migrated Asian communities.
Assuntos
Menopausa/etnologia , Menopausa/fisiologia , Afeto , Ansiedade , Estudos Transversais , Escolaridade , Emigrantes e Imigrantes , Feminino , Fogachos , Humanos , Índia/etnologia , Estilo de Vida , Estado Civil , Pessoa de Meia-Idade , Perimenopausa , Pós-Menopausa/etnologia , Pós-Menopausa/fisiologia , Religião , Inquéritos e Questionários , Reino Unido , Sistema Vasomotor/fisiologia , Saúde da MulherRESUMO
OBJECTIVES: To determine, first, the effects of menopausal status on circulating calcitonin gene-related peptide (CGRP) levels and, second, the correlation between circulating CGRP levels and biomarkers for cardiovascular disease. METHODS: Cross-sectional study of healthy premenopausal and postmenopausal women volunteers and women admitted for elective benign abdominal surgery in a district general hospital. All women were non-smokers, had no history of endocrinological problems and were not receiving any hormone therapy. Fasting blood samples (premenopausal (n = 45): follicle stimulating hormone (FSH) < 20 IU/l, estradiol (mean +/- SEM) 440.33 +/- 51.82 pmol/l; postmenopausal women (n = 28): FSH > 20 IU/l, estradiol 93.79 +/- 17.40 pmol/l) were analyzed for CGRP, resistin, leptin, adiponectin, insulin and lipids using ELISA and immunoassays. RESULTS: Mean circulating CGRP levels were higher in the postmenopausal women compared with premenopausal women (pre: 41.79 +/- 9.01 pg/ml, post: 138.14 +/- 45.75 pg/ml; p = 0.047). Among women who were experiencing hot flushes, the postmenopausal women had significantly higher CGRP levels than the premenopausal women (pre: 21.98 +/- 4.95 pg/ml, post: 171.08 +/- 61.80 pg/ml; p = 0.028). Serum CGRP levels positively correlated with serum insulin levels (r = 0.652, p = 0.016) and HOMA index (r = 0.54, p < 0.001). CONCLUSION: These data show that circulating CGRP levels are influenced by menopausal status and suggest additional mechanisms through which increased risk of hyperinsulinemia and cardiovascular disease may arise in postmenopausal women.
Assuntos
Adipocinas/sangue , Peptídeo Relacionado com Gene de Calcitonina/sangue , Pós-Menopausa/sangue , Pré-Menopausa/sangue , Adulto , Índice de Massa Corporal , Colesterol/sangue , Estudos Transversais , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Fogachos/sangue , Humanos , Insulina/sangue , Resistência à Insulina , Pessoa de Meia-Idade , Triglicerídeos/sangueAssuntos
Terapia de Reposição Hormonal , Menopausa , Neoplasias da Mama/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Cognição/efeitos dos fármacos , Feminino , Fraturas Ósseas/prevenção & controle , Educação em Saúde , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Meios de Comunicação de Massa , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Acidente Vascular Cerebral/epidemiologia , Tromboembolia/epidemiologia , Fatores de TempoAssuntos
Envelhecimento , Terapia de Reposição de Estrogênios/efeitos adversos , Terapia de Reposição de Estrogênios/métodos , Nível de Saúde , Menopausa , Guias de Prática Clínica como Assunto , Idoso , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Medicina Baseada em Evidências , Feminino , Humanos , Pessoa de Meia-Idade , Osteoporose Pós-Menopausa/epidemiologia , Osteoporose Pós-Menopausa/prevenção & controle , Seleção de Pacientes , Pós-MenopausaRESUMO
OBJECTIVE: To evaluate the effect of two ultra-low-dose hormone treatments containing estradiol (E2) 0.5 mg and norethisterone acetate (NETA) 0.1 or 0.25 mg on the endometrium and bleeding. METHODS: A prospective, randomized, placebo-controlled trial of 6 months. Local Ethics Committee approval and informed consent were obtained prior to initiation and enrollment. Out of 577 postmenopausal women randomized, 575 took E2/NETA 0.1 (n = 194), or E2/NETA 0.25 (n = 181) or placebo (n = 200). Endometrial bleeding was monitored by daily diary cards and endometrial thickness by transvaginal ultrasound at baseline and on completion. An endometrial biopsy was obtained when indicated clinically. RESULTS: In months 1-6, the amenorrhea rates with E2/NETA 0.1 were 89%, 89%, 86%, 85%, 89% and 89%, respectively and the no-bleeding rates were correspondingly high: 95%, 94%, 93%, 90%, 95% and 95%. The amenorrhea and spotting-only rates were similar with both ultra-low-dose combinations. The withdrawal rates due to bleeding were very low and the same in all three treatment arms (n = 1; 1%). There was a slight increase in the mean endometrial thickness in all three groups, which remained less than 5 mm. CONCLUSIONS: The ultra-low-dose combination of E2/NETA 0.1 or E2/NETA 0.25 resulted in a high incidence of amenorrhea and no bleeding in postmenopausal women, and a corresponding high level of compliance. Overall, there was no significant change in mean endometrial thickness during 6 months of active treatment or placebo.
Assuntos
Amenorreia/induzido quimicamente , Anticoncepcionais Orais Sintéticos/farmacologia , Endométrio/efeitos dos fármacos , Estradiol/farmacologia , Noretindrona/análogos & derivados , Pós-Menopausa , Hemorragia Uterina/induzido quimicamente , Adulto , Idoso , Amenorreia/epidemiologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Endométrio/diagnóstico por imagem , Endométrio/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Noretindrona/farmacologia , Acetato de Noretindrona , Estudos Prospectivos , Ultrassonografia , Hemorragia Uterina/epidemiologiaRESUMO
There have been few additional published data concerning the effects of hormone replacement therapy (HRT) on the endometrium since December 2003. The Million Women Study has confirmed the known protective effect of progestogen with both sequential and continuous combined regimens, although also reporting an increased risk of endometrial cancer with tibolone. This finding has not been found in any other study previously or in the recently reported OPAL 3-year study. Bleeding during HRT remains an important issue for patient acceptability as well as physician concern about the implications. The incidence of bleeding is related to the dose of estrogen and the development of new low-dose therapies containing 0.5 mg oral estradiol, 0.3 mg oral conjugated equine estrogens or 14 microg estradiol daily by transdermal patch is associated with less bleeding and thus greater patient acceptability as well as minimal endometrial stimulation. Intrauterine delivery of progestogen is the most logical route of administration and provides a high level of progestogen directly to the endometrium, with good endometrial suppression and lower circulating levels than by other routes. The protective effect of progestogen on the endometrium has to be balanced against the apparent adverse effect on breast cancer risk.